William Charles Montgomery
Plus aucun poste en cours
Profil
William Charles Montgomery has been Senior Vice President of Business Development and Alliance Management for AtheroGenics, Inc. since May 2006, after serving as Vice President of Business Development since 2004.
He had served as Vice President of Business Development and Portfolio Planning for Celera Genomics since 2002.
From 1987 to 2001, he served in various senior positions for the DuPont Pharmaceuticals Company and the DuPont Merck Pharmaceutical Company, most recently as Vice President and Co-Head of Business Development and Strategic Planning.
Dr. Montgomery received a BS in Chemistry from Southern Methodist University in Dallas, Texas and a PhD in Organic Chemistry from the University of Minnesota.
Anciens postes connus de William Charles Montgomery
Sociétés | Poste | Fin |
---|---|---|
AtheroGenics, Inc.
AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Corporate Officer/Principal | 14/07/2009 |
Celera Group
Celera Group Pharmaceuticals: MajorHealth Technology Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD | Corporate Officer/Principal | 01/01/2004 |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | 01/01/2001 |
Formation de William Charles Montgomery
Southern Methodist University | Undergraduate Degree |
University of Minnesota | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
AtheroGenics, Inc.
AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis. | Health Technology |
Celera Group
Celera Group Pharmaceuticals: MajorHealth Technology Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |